Jaclyn Louise Henderson

This inventor holds 18 USPTO granted patents and 6 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Dopamine Ligands. Top assignee: Pfizer Corporation. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jaclyn Louise Henderson. Retrieved from https://idiyas.com/inventor/jaclyn-louise-henderson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 11.4

ph-index = 5

Forward Citations = 69(Granted Patents)

Company Filing History:

18 out of 4,488

Pfizer Corporation

patents

Years Active: 2015-2024

Loading Chart...

Areas of Expertise:

Dopamine D1

Dopamine D3

LRRK2 Inhibitors

Heteroaromatic Compounds

Imidazoquinolines

Pyrrolo Compounds

Ligands

Cyclic Derivatives

Substituted Amino

Pyrimidines

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11964961 - Heteroaromatic compounds and their use as dopamine D1 ligands (2024-04-23),

2. 11390623 - 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands (2022-07-19),

3. 11312713 - Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors (2022-04-26),

4. 11161844 - Cyclic substituted imidazo[4,5-c]quinoline derivatives (2021-11-02),

5. 11014909 - Heteroaromatic compounds and their use as dopamine D1 ligands (2021-05-25),

6. 10696658 - Heteroaromatic compounds and their use as dopamine D1 ligands (2020-06-30),

7. 10590128 - 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands (2020-03-17),

8. 10421744 - Heteroaromatic compounds and their use as dopamine D1 ligands (2019-09-24),

9. 10093655 - Heteroaromatic compounds and their use as dopamine D1 ligands (2018-10-09),

10. 10039753 - Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors (2018-08-07),

11. 9822097 - Heteroaromatic compounds and their use as dopamine D1 ligands (2017-11-21),

12. 9695171 - 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors (2017-07-04),

13. 9642855 - Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors (2017-05-09),

14. 9617275 - Heteroaromatic compounds and their use as dopamine D1 ligands (2017-04-11),

15. 9527831 - Heteroaromatic compounds and their use as dopamine D1 ligands (2016-12-27),

Title: Jaclyn Louise Henderson: Pioneering Contributions in Pharmacological Innovations

Introduction: Jaclyn Louise Henderson, a prolific inventor based in Cambridge, MA, has made substantial contributions to the field of pharmacology, amassing an impressive portfolio of 18 patents. Her work primarily focuses on developing innovative compounds aimed at treating various neurological and psychiatric disorders.

Latest Patents: Among her latest inventions is the patent for heteroaromatic compounds used as dopamine D1 ligands. This invention introduces compounds that can effectively treat a wide range of D1-mediated disorders such as schizophrenia, ADHD, autism spectrum disorder, and various mood disorders. Another significant patent involves 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands, which are poised to address disorders related to substance addiction, depression, and impulse control.

Career Highlights: Jaclyn Louise Henderson is currently associated with Pfizer Corporation, where she applies her innovative mindset to advance the company's pharmacological research. Her extensive background in medicinal chemistry and drug development has played a crucial role in her ability to create effective therapeutic solutions.

Collaborations: Throughout her career, Jaclyn has collaborated with esteemed colleagues, including Lei Zhang and Michael Aaron Brodney. Their combined expertise often leads to groundbreaking advancements in the pharmaceutical field, further enhancing the impact of their collective research.

Conclusion: Jaclyn Louise Henderson’s dedication to innovation in the pharmaceutical industry reflects her commitment to enhancing treatment options for numerous psychological and neurological conditions. With her significant number of patents and collaborative spirit, she continues to be a vital asset in the pursuit of medical advancement.

Profile summary based on public USPTO records.